Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05103176
Other study ID # HUM00186637
Secondary ID 1R21NS118055-01A
Status Recruiting
Phase N/A
First received
Last updated
Start date February 15, 2022
Est. completion date July 2024

Study information

Verified date August 2023
Source University of Michigan
Contact Ashley Rettmann
Phone 734-763-2790
Email arettman@umich.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repetitive transcranial magnetic stimulation (rTMS) is a powerful tool to non-invasively modulate brain circuits, brain plasticity, and behavior. This proposal will test the hypothesis that controlling behavioral state during focal multi-day rTMS of a brain region involved in grasping movements will enhance the functional specificity of the neuromodulation action among distributed brain regions involved in voluntary motor control and concomitantly improve manual dexterity. Results from this study will be used to optimize rTMS therapy for individuals with neuromotor impairments by controlling behavioral state to improve the efficacy of rTMS treatment. Healthy volunteers that qualify for this study will have motor skill assessments and basic neuromotor testing (using neurophysiology with TMS and functional Magnetic Resonance Imaging (fMRI) scans). Participants will be asked to come in for up to nine sessions that include 1 screening session, 5 consecutive daily rTMS sessions and 3 assessment sessions with resting-state and task-based fMRI, neurophysiology with TMS, and hand motor tasks over the course of 3-4 weeks.


Description:

This study will examine a particular type of rTMS, known as theta burst stimulation (TBS), which has been shown to induce longer lasting effects than other forms of rTMS, making TBS an important tool for therapeutic applications. While TBS provides relatively focal stimulation, effects on the brain occur through interconnected networks in ways that are poorly understood. Moreover, stimulation is highly state-dependent, and the use of rTMS in most therapeutic settings, such as the treatment of motor impairments, leaves behavioral state uncontrolled. Augmenting rTMS therapy by inducing specific behavioral states is an attractive idea for improving therapeutic rTMS, but the relevant knowledge base is sparse. To address this critical gap, this exploratory R21 proposal will examine the effects of TBS and behavioral state on brain and motor behavior. The investigators will test the broad hypothesis that when TBS is applied during a controlled behavior state, motor function will be facilitated, compared to stimulation when behavioral state is uncontrolled. The investigators will focus on the posterior parietal cortex (PPC), and associated parietofrontal circuits, which subserve skilled grasp control, an ability known to be impaired in stroke, traumatic brain injury, and other motor disorders. The investigators will collect functional magnetic resonance imaging (fMRI), neurophysiological measures with TMS, and behavioral measures in all subjects for three different interventions. In Aim 1, the investigators will show improvement in action performance by manipulating the behavioral state during PPC stimulation. In Aim 2, the investigators will demonstrate modulation of neurophysiological aftereffects of PPC stimulation on motor output by manipulating behavioral state. In Aim 3, the investigators will assess the relationship between brain connectivity, plasticity and behavior in response to the behavioral state during brain stimulation. Impact: Results will provide insights into the effects of rTMS and behavioral state on the brain and behavior. This knowledge will lay a mechanistic foundation for future studies to show how controlling behavioral state during rTMS can improve therapeutic efficacy in neurological disorders.


Recruitment information / eligibility

Status Recruiting
Enrollment 65
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Women of child bearing age cannot be pregnant or trying to become pregnant - Ability to tolerate small, enclosed spaces without anxiety - Ability and willingness to give informed consent to participate - No history of neurological disorder - Right handed - English speaking Exclusion Criteria: - Are left-handed - Are younger than 18 or older than 50 years old - Women who are pregnant, suspect they are pregnant, or are attempting to become pregnant - Have metal anywhere in the head, excluding the mouth - Have a pacemaker, deep brain stimulator, vagus nerve stimulator or any other medically implanted device - Have cochlear hearing implants - Are taking GABAergic, NDMA-receptor antagonist, or other drug known to influence neural receptors - Have any of the below conditions that would put participants at increased risk of having a seizure: a personal or family history of seizure/epilepsy, taking prescription drugs that lower the threshold for seizures, recent history of excessive alcohol consumption, history of alcohol addiction/dependence, recent history of recreational drug use, history of drug addiction/dependence - Have been diagnosed with any of the following: a stroke, brain hemorrhage, brain tumor, encephalitis, multiple sclerosis, Parkinson's disease or Alzheimer's disease, depression in the past 6 months, attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder, normal pressure hydrocephalus or increased intra-cranial pressure, diabetes requiring insulin treatment, any serious heart disorder or liver disease - Have had a migraine in the past month - MRI specific exclusion criteria: Any relevant history of open-heart surgery, artificial heart valve, brain aneurysm surgery, braces or extensive dental work, cataract surgery or lens implant, or artificial limb or joint. History of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or metalwork fragments. Claustrophobia, have uncontrollable shaking, or cannot lie still for one hour.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TMS
A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
Behavioral:
Object directed grasping
Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After ~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every "GO" cue in order to modulate cortical activity during both the planning and execution phase of the action.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage change in the time to complete the nine-hole peg test (9-HPT) to immediate post-intervention 9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds) Baseline and immediate post-intervention (up to 30 min)
Primary Percentage change in amplitude of motor evoked potential (MEP) to immediate post-intervention. Motor cortical excitability is measured by electromyography using MEPs elicited by TMS Baseline and immediate post-intervention (up to 60 min)
Primary Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to immediate post-intervention. Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC Baseline and immediate post-intervention (up to 60 min during fMRI)
Primary Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to immediate post-intervention. Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task Baseline and immediate post-intervention (up to 60 min during fMRI)
Secondary Percentage change in the time to complete the nine-hole peg test (9-HPT) to 1-week post-intervention 9-hole peg test is a manual dexterity measure, estimated as the time required to complete the task (seconds) Baseline and 1-week post-intervention (up to 30 min)
Secondary Percentage change in amplitude of motor evoked potential (MEP) to 1-week post-intervention. Motor cortical excitability is measured by electromyography using MEPs elicited by TMS Baseline and 1-week post-intervention (up to 60 min)
Secondary Change from baseline functional connectivity to PPC stimulation target within the cortical grasping network to 1-week post-intervention. Resting-state connectivity of low frequency BOLD fluctuations for a seed at the PPC Baseline and 1-week post-intervention (up to 60 min during fMRI)
Secondary Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in the cortical grasp network to 1-week post-intervention. Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task Baseline and 1-week post-intervention (up to 60 min during fMRI)
Secondary Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to immediate post-intervention. Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task Baseline and immediate-intervention (up to 60 min during fMRI)
Secondary Change from baseline Blood Oxygen Level-Dependent (BOLD) activation, voxelwise in whole brain to 1-week post-intervention. Parietal-frontal cortical grasping network defined by BOLD change while subject performs the precision force-tracking task Baseline and 1-week post-intervention (up to 60 min during fMRI)
Secondary Percentage change in accuracy to precision force-tracking task to immediate post-intervention Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE) Baseline and immediate post-intervention (up to 60 min during fMRI and outside scanner)
Secondary Percentage change in accuracy to precision force-tracking task to 1-week post-intervention Squared distance (error) from the cursor to the target in precision force-tracking task, estimated as the root mean squared error (RMSE) Baseline and 1-week post-intervention (up to 60 min during fMRI and outside scanner)
Secondary Percentage change in the mean choice reaction time to immediate post-intervention Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses Baseline and immediate post-intervention (up to 30 min)
Secondary Percentage change in the mean choice reaction time to 1-week post-intervention Mean reaction time for subjects responding in the 2-choice reaction time control task, for correct responses Baseline and 1-week post-intervention (up to 30 min)
Secondary Percentage change in the normalized motor evoked potential (MEP) size to immediate post-intervention. Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest Baseline and immediate post-intervention (up to 60 min)
Secondary Percentage change in the normalized motor evoked potential (MEP) size to 1-week post-intervention. Parietal-motor functional connectivity is measured by electromyography using MEPs elicited by dual-site TMS, while subjects perform an object-directed grasp/subjects are at rest Baseline and 1-week post-intervention (up to 60 min)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1